Kamal Hamed is Chief Medical Officer of Spero Therapeutics, Inc.. Currently has a direct ownership of 788,117 shares of SPRO, which is worth approximately $811,760. The most recent transaction as insider was on Feb 02, 2024, when has been sold 28,075 shares (Common Stock) at a price of $1.37 per share, resulting in proceeds of $38,462. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 788K
0% 3M change
36.72% 12M change
Total Value Held $811,760

KAMAL HAMED Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 02 2024
SELL
Open market or private sale
$38,462 $1.37 p/Share
28,075 Reduced 3.44%
788,117 Common Stock
Feb 01 2024
BUY
Grant, award, or other acquisition
-
239,731 Added 22.7%
816,192 Common Stock
Sep 13 2023
SELL
Open market or private sale
$50,159 $1.27 p/Share
39,496 Reduced 6.41%
576,461 Common Stock
Jun 12 2023
BUY
Grant, award, or other acquisition
-
140,000 Added 18.52%
615,957 Common Stock
Feb 01 2023
BUY
Grant, award, or other acquisition
-
265,957 Added 35.85%
475,957 Common Stock
Sep 12 2022
BUY
Grant, award, or other acquisition
-
210,000 Added 50.0%
210,000 Common Stock
KH

Kamal Hamed

Chief Medical Officer
Cambridge, MA

Track Institutional and Insider Activities on SPRO

Follow Spero Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SPRO shares.

Notify only if

Insider Trading

Get notified when an Spero Therapeutics, Inc. insider buys or sells SPRO shares.

Notify only if

News

Receive news related to Spero Therapeutics, Inc.

Track Activities on SPRO